Environmental research · 2026
Urinary arsenic levels and risk of breast cancer among women in the Canadian health measures survey: a population-based prospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pullella Katherine, Chang Vicky C, Giannakeas Vasily, Lubiński Jan, Harris Shelley A, Hanley Anthony J, Narod Steven A, Kotsopoulos Joanne
Аннотация
INTRODUCTION: Arsenic is an established carcinogen for skin, bladder and lung cancers; however, the relationship between arsenic exposure and breast cancer risk is not well defined. Previous studies focused on populations exposed to high arsenic, and the impact of persistent, low-level exposure remains unclear. This study evaluated the association between urinary arsenic levels and breast cancer risk among Canadian women.
METHODS: Demographic information and urinary arsenic biomarkers (μg/L) from Cycles 1-5 (2007-2017) of the Canadian Health Measures Survey were analyzed. Arsenic exposure was categorized into quartiles. Incident breast cancers (invasive, lobular, and ductal carcinoma in situ) were ascertained through linkage to the Canadian Cancer Registry and Discharge Abstract Database. Multivariable Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95 % confidence intervals (CI) of arsenic exposure and breast cancer risk.
RESULTS: The analysis represented 6,070,000 women, with 73,700 incident breast cancers identified over 6.6 years of follow-up. The geometric mean for urinary arsenic was 10.7 μg/L (range: 2.70-84.83 μg/L). Women in the highest quartile of total urinary arsenic levels (≥21.8 μg/L) had a three-fold increased risk of developing breast cancer compared to women with lower levels (HR = 3.06, 95 % CI 1.10-8.49, P-value = 0.03).
CONCLUSIONS: This represents the first analysis of arsenic levels and breast cancer risk in a nationally representative, Canadian cohort. Findings suggest that exposure to arsenic, even at low levels, may be associated with an increased risk of breast cancer, underscoring the need for population-level interventions to reduce the breast cancer burden in Canada.
METHODS: Demographic information and urinary arsenic biomarkers (μg/L) from Cycles 1-5 (2007-2017) of the Canadian Health Measures Survey were analyzed. Arsenic exposure was categorized into quartiles. Incident breast cancers (invasive, lobular, and ductal carcinoma in situ) were ascertained through linkage to the Canadian Cancer Registry and Discharge Abstract Database. Multivariable Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95 % confidence intervals (CI) of arsenic exposure and breast cancer risk.
RESULTS: The analysis represented 6,070,000 women, with 73,700 incident breast cancers identified over 6.6 years of follow-up. The geometric mean for urinary arsenic was 10.7 μg/L (range: 2.70-84.83 μg/L). Women in the highest quartile of total urinary arsenic levels (≥21.8 μg/L) had a three-fold increased risk of developing breast cancer compared to women with lower levels (HR = 3.06, 95 % CI 1.10-8.49, P-value = 0.03).
CONCLUSIONS: This represents the first analysis of arsenic levels and breast cancer risk in a nationally representative, Canadian cohort. Findings suggest that exposure to arsenic, even at low levels, may be associated with an increased risk of breast cancer, underscoring the need for population-level interventions to reduce the breast cancer burden in Canada.